ERBB2 and neoplasm: We prioritised APOBEC associated mutational signatures for further analysis given the frequency of the signatures in HER2+ pre-treatment tumours and having robustly confirmed detection across two methods and analogous mutational signature reference sets (Supplementary Table 7.2).